Product Images Clopidogrel

This is a table that shows the Hazard Ratio for Patient Baseline Characteristics and medications/interventions, for the CURE Study. The table includes data on subgroups based on variables such as Hepari/INWH, Aspirin(mg), GPIIHTIa Antag, Beta-Blocker, and Ace Inhibitor. The data is presented in terms of patient numbers, percentage of patients receiving clopidogrel and placebo, and the hazard ratio (95%CT).*

This text presents a figure showing the effects of adding clopidogrel to aspirin on the combined primary endpoint across baseline and concomitant medication subgroups for the COMMIT study. The figure provides information on the number of participants, percentage values, and Odds Ratio for each subgroup, such as Gender, Heart Rate, and Fibrinolytic Agent Given. The table includes two columns: "Placebo" and "Favors Clopidogrel," indicating the percentage of patients who experienced favorable outcomes.*

The figure shows the cumulative event rate of fatal or non-fatal vascular events in the CAPRIE study over 18 months of follow-up. Clopidogrel had a statistically significant lower risk compared to aspirin.*

This is a figure that shows the impact of different proton pump inhibitors (PPIs) on the exposure to Clopidogrel active metabolite, based on multiple doses of 75mg of Clopidogrel alone or with PPI. The impact is measured through the mean and 90% confidence interval of the active metabolite area under the curve (AUC). The figure shows the results for Dextansoprazole (60mg), Lansoprazole (30mg), Pastoprazole (50mg), and Omeprazole (80mg). There is a scale that shows the change relative to Clopidogrel administered alone.*

The text describes Figure 2 of a study called "CURE study" which shows the percentage of cumulative events related to cardiovascular death, myocardial infarction, and stroke in a group of patients who were given different types of medication. The study compares the effects of using aspirin and placebo versus using clopidogrel and aspirin. The graph shows that the cumulative event rate was significantly lower in the clopidogrel and aspirin group compared to the group who received placebo and aspirin. The text also notes that other standard therapies were employed.*

Cumulative event rates for death in the COMMIT study are shown in Figure 4. About 81% of the patients in the placebo group had died (1815 deaths) and 75% in the active treatment group had died (172 deaths). The proportional risk reduction was 7% (p-value of 0.033), with a hazard ratio of 0.79 (95% CI 0.65-0.97). The study included all suited patients who received treatment.*

This is a figure from the COMMIT study, showing the cumulative event rates for the combined endpoint of re-infarction, stroke or death. The placebo group had 2310 events (10.1%), while the clopidogrel group had 2121 events (8.2%). The reduction in proportionate risk was 9%, with a reduction in death of 6%, and a reduction in re-infarction and stroke occurring before first dischange of 7%. The data was collected from patients who had all received aspirin. Days since randomization are shown on the x-axis, up to 28 days.*